207 related articles for article (PubMed ID: 33428142)
1. TMEM158 May Serve as a Diagnostic Biomarker for Anaplastic Thyroid Carcinoma: An Integrated Bioinformatic Analysis.
Li HN; Du YY; Xu T; Zhang R; Wang G; Lv ZT; Li XR
Curr Med Sci; 2020 Dec; 40(6):1137-1147. PubMed ID: 33428142
[TBL] [Abstract][Full Text] [Related]
2. Identification of Key Pathways and Genes in Anaplastic Thyroid Carcinoma via Integrated Bioinformatics Analysis.
Hu S; Liao Y; Chen L
Med Sci Monit; 2018 Sep; 24():6438-6448. PubMed ID: 30213925
[TBL] [Abstract][Full Text] [Related]
3. Identification of Hub Genes in Anaplastic Thyroid Carcinoma: Evidence From Bioinformatics Analysis.
Li L; Zhu M; Huang H; Wu J; Meng D
Technol Cancer Res Treat; 2020; 19():1533033820962135. PubMed ID: 33025856
[TBL] [Abstract][Full Text] [Related]
4. Integrated Bioinformatics Analysis of Master Regulators in Anaplastic Thyroid Carcinoma.
Pan Z; Li L; Fang Q; Qian Y; Zhang Y; Zhu J; Ge M; Huang P
Biomed Res Int; 2019; 2019():9734576. PubMed ID: 31183379
[TBL] [Abstract][Full Text] [Related]
5. Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.
Weinberger P; Ponny SR; Xu H; Bai S; Smallridge R; Copland J; Sharma A
Thyroid; 2017 Feb; 27(2):236-252. PubMed ID: 27796151
[TBL] [Abstract][Full Text] [Related]
6. Recognition of Key Genes in Human Anaplastic Thyroid Cancer via the Weighing Gene Coexpression Network.
Gong Y; Xu F; Deng L; Peng L
Biomed Res Int; 2022; 2022():2244228. PubMed ID: 35782055
[TBL] [Abstract][Full Text] [Related]
7. Identification of key candidate genes and pathways in anaplastic thyroid cancer by bioinformatics analysis.
Ding YG; Ren YL; Xu YS; Wei CS; Zhang YB; Zhang SK; Guo CA
Am J Otolaryngol; 2020; 41(3):102434. PubMed ID: 32093976
[TBL] [Abstract][Full Text] [Related]
8. Genes and pathways identified in thyroid carcinoma based on bioinformatics analysis.
Yu JW; Mai W; Cui YL; Kong LY
Neoplasma; 2016; 63(4):559-68. PubMed ID: 27268919
[TBL] [Abstract][Full Text] [Related]
9. Identification of key pathways and biomarkers in anaplastic thyroid cancer using an integrated analysis.
Zhou J; Dong S; Shi C
J BUON; 2020; 25(6):2690-2699. PubMed ID: 33455115
[TBL] [Abstract][Full Text] [Related]
10. [Identification of key pathways and drug repurposing for anaplastic thyroid carcinoma by integrated bioinformatics analysis].
Pan Z; Fang Q; Zhang Y; Li L; Huang P
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2018 May; 47(2):187-193. PubMed ID: 30226315
[TBL] [Abstract][Full Text] [Related]
11. Identification of key genes associated with papillary thyroid microcarcinoma characteristics by integrating transcriptome sequencing and weighted gene co-expression network analysis.
Yang F; Lian M; Ma H; Feng L; Shen X; Chen J; Fang J
Gene; 2022 Feb; 811():146086. PubMed ID: 34856364
[TBL] [Abstract][Full Text] [Related]
12. Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.
Xu T; Ruan H; Song Z; Cao Q; Wang K; Bao L; Liu D; Tong J; Yang H; Chen K; Zhang X
Biomed Pharmacother; 2019 Oct; 118():109264. PubMed ID: 31390578
[TBL] [Abstract][Full Text] [Related]
13. IGF2BP1 is the first positive marker for anaplastic thyroid carcinoma diagnosis.
Haase J; Misiak D; Bauer M; Pazaitis N; Braun J; Pötschke R; Mensch A; Bell JL; Dralle H; Siebolts U; Wickenhauser C; Lorenz K; Hüttelmaier S
Mod Pathol; 2021 Jan; 34(1):32-41. PubMed ID: 32719445
[TBL] [Abstract][Full Text] [Related]
14. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression.
Ma Y; Cang S; Li G; Su Y; Zhang H; Wang L; Yang J; Shi X; Qin G; Yuan H
J Cell Physiol; 2019 Dec; 234(12):22260-22271. PubMed ID: 31081124
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of an inhibitor of cell growth, transmembrane protein 34 (TMEM34), in anaplastic thyroid cancer.
Akaishi J; Onda M; Okamoto J; Miyamoto S; Nagahama M; Ito K; Yoshida A; Shimizu K
J Cancer Res Clin Oncol; 2007 Apr; 133(4):213-8. PubMed ID: 17072649
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel characteristic biomarkers and immune infiltration profile for the anaplastic thyroid cancer via machine learning algorithms.
Li C; Dong X; Yuan Q; Xu G; Di Z; Yang Y; Hou J; Zheng L; Chen W; Wu G
J Endocrinol Invest; 2023 Aug; 46(8):1633-1650. PubMed ID: 36725810
[TBL] [Abstract][Full Text] [Related]
17. Weighted gene co-expression network reveals driver genes contributing to phenotypes of anaplastic thyroid carcinoma and immune checkpoint identification for therapeutic targets.
Dong X; Yang Y; Hou J; Chen W; Yuan Q; Xu G; Liu J; Li C; Wu G
Front Oncol; 2022; 12():1018479. PubMed ID: 36530988
[TBL] [Abstract][Full Text] [Related]
18. miRNA expression in anaplastic thyroid carcinomas.
Hébrant A; Floor S; Saiselet M; Antoniou A; Desbuleux A; Snyers B; La C; de Saint Aubain N; Leteurtre E; Andry G; Maenhaut C
PLoS One; 2014; 9(8):e103871. PubMed ID: 25153510
[TBL] [Abstract][Full Text] [Related]
19. Integrated Bioinformatics Analysis of Hub Genes and Pathways in Anaplastic Thyroid Carcinomas.
Gao X; Wang J; Zhang S
Int J Endocrinol; 2019; 2019():9651380. PubMed ID: 30774662
[TBL] [Abstract][Full Text] [Related]
20. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
